Head-to-head evidence
HLX04-O vs Pegaptanib (Macugen)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
HLX04-O
Developed by Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
The trial randomized 410 participants to HLX04-O or the active comparator ranibizumab and masked both participants and investigators. Its primary clinical endpoint was the mean change in best-corrected visual acuity at Week 36, but no statistical comparison or outcome result is available yet.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Pegaptanib (Macugen)
Marketed by Pfizer
NCT01100307 · Phase 3 · completed
This was a randomized, double-masked, sham-controlled phase 3 trial with 243 participants and a hard clinical visual-acuity endpoint. The primary endpoint was met: 25 of 123 participants receiving pegaptanib versus 6 of 120 receiving sham achieved at least a 10-letter improvement at week 24 (p=0.0003).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX04-O's landscape · Pegaptanib (Macugen)'s landscape